Zomedica Revenue Growth Rates (ZOMDF), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Zomedica Corp   (NONE: ZOMDF)
 

ZOMDF's Revenue Growth by Quarter and Year

Zomedica 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/ZOMDF/growth
https://api.csimarket.com/api/v1/companies/ZOMDF/fundamentals
https://api.csimarket.com/api/v1/companies/ZOMDF/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
Explore the Financial Data API
Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery
Connect Your AI Assistant
How to Connect Your AI Assistant to CSIMarket MCP MCP Server
Access this full dataset via API
Free sample Full docs All endpoints
ZOMDF Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 9.90
2nd Quarter June 9.51
1st Quarter March 8.48
FY 27.89

ZOMDFs Annual Revenue
Zomedica 's Revenue in the fiscal year 2025 $ 31.68 millions
Zomedica 's Revenue in the fiscal year 2024 $ 27.09 millions
Zomedica 's Revenue in the fiscal year 2023 $ 24.32 millions
Zomedica 's Revenue in the fiscal year 2022 $ 18.93 millions
Zomedica 's Revenue in the fiscal year 2020 $ -0.03 millions




ZOMDF Revenue third quarter 2026 Y/Y Growth Comment
Zomedica Corp reported Revenue improvement of 33.05% year on year in the third quarter 2026, to $ 9.90 millions, this is lower than Zomedica Corp 's recent average Revenue surge of 2617.33%.

Looking into third quarter 2026 results within Major Pharmaceutical Preparations industry 101 other companies have achieved higher Revenue growth. While Zomedica Corp ' s Revenue rise of 33.05% ranks overall at the positon no. 1974 in the third quarter 2026.


ZOMDF Revenue ( Y/Y Growth %) 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 33.05 %
2nd Quarter June 36.64 %
1st Quarter March 32.29 %
FY   -

Financial Statements
Zomedica 's third quarter 2026 Revenue $ 9.90 millions ZOMDF's Income Statement
Zomedica 's third quarter 2025 Revenue $ 7.44 millions Quarterly ZOMDF's Income Statement


ZOMDF Revenue (Quarter on Quarter Growth %)

 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 4.09 %
2nd Quarter June 12.15 %
1st Quarter March -19.01 %
FY (Year on Year)   -


Back to ZOMDF Growth rate Comparisons >> Back to ZOMDF Growth rate Comparisons >>


Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #102
Healthcare Sector #305
Overall #1974

Revenue Y/Y Growth Statistics
High Average Low
41049.97 % 2617.33 % 9.71 %
(Sep 30 2022)   (Mar 31 2025)
Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #102
Healthcare Sector #305
Overall #1974
Revenue Y/Y Growth Statistics
High Average Low
41049.97 % 2617.33 % 9.71 %
(Sep 30 2022)   (Mar 31 2025)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Zomedica 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
18025.58 % 867.55 % -32.9 %
(Dec 31 2021)  


ZOMDF's III. Quarter Q/Q Revenue Comment
Zomedica Corp achieved in the III. Quarter 2026 below company average Revenue growth of 4.09% quarter on quarter, to $ 9.90 millions.

Within Major Pharmaceutical Preparations industry 52 other companies have achieved higher Revenue quarter on quarter growth. While Zomedica 's Revenue growth quarter on quarter, overall rank is 731.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #53
Healthcare Sector #121
Overall #731
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #53
Healthcare Sector #121
Overall #731
Revenue Q/Q Growth Statistics
High Average Low
18025.58 % 867.55 % -32.9 %
(Dec 31 2021)  


ZOMDF's III. Quarter Q/Q Revenue Comment
Zomedica Corp achieved in the III. Quarter 2026 below company average Revenue growth of 4.09% quarter on quarter, to $ 9.90 millions.

Within Major Pharmaceutical Preparations industry 52 other companies have achieved higher Revenue quarter on quarter growth. While Zomedica 's Revenue growth quarter on quarter, overall rank is 731.


Zomedica 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2026)		 12 Months Ending (Mar 31 2026) 12 Months Ending (Dec 31 2025) 12 Months Ending (Sep 30 2025) 12 Months Ending (Jun 30 2025)
Cumulative Revenue 12 Months Ending $ 35.90
Y / Y Revenue Growth (TTM) 23.89 %
Year on Year Revenue Growth Overall Ranking # 1132
Seqeuential Revenue Change (TTM) 7.64 %
Seq. Revenue Growth (TTM) Overall Ranking # 1979


Cumulative Revenue growth Comment
Although Zomedica 's Annual Revenue growth year on year were below company's average 2617.33% , Revenue announced in the Jun 30 2026 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 23.89% year on year, from 21.84% in Mar 31 2026.

In the Healthcare sector 209 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 1053 to 1132.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 102
Healthcare Sector # 210
Overall # 1132

Revenue TTM Y/Y Growth Statistics
High Average Low
41049.97 %
 2617.33 %
9.71 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 102
Sector # 305
S&P 500 # 1979
Cumulative Revenue growth Comment
Although Zomedica 's Annual Revenue growth year on year were below company's average 2617.33% , Revenue announced in the Jun 30 2026 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 23.89% year on year, from 21.84% in Mar 31 2026.

In the Healthcare sector 209 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 1053 to 1132.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 102
Healthcare Sector # 210
Overall # 1132

Revenue TTM Y/Y Growth Statistics
High Average Low
41049.97 %
2617.33 %
9.71 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 102
Sector # 305
S&P 500 # 1979




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
ZOMDF's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue growth for the quarter ending Sep 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2026
Envoy Medical Inc 57.14%$ 57.143 millions
Humacyte Inc 55.21%$ 55.208 millions
Butterfly Network Inc 53.45%$ 53.453 millions
Avita Medical Inc 53.05%$ 53.054 millions
Immunitybio inc 52.34%$ 52.338 millions
Axsome Therapeutics Inc 51.87%$ 51.873 millions
Yunhong Green Cti Ltd 51.28%$ 51.282 millions
Innovative Eyewear Inc 51.12%$ 51.123 millions
Strata Critical Medical Inc 50.27%$ 50.272 millions
Madrigal Pharmaceuticals Inc 50.13%$ 50.127 millions
Immucell Corporation49.91%$ 49.912 millions
Hims and Hers Health Inc 48.88%$ 48.877 millions
Maxcyte inc 48.66%$ 48.660 millions
Billiontoone Inc 47.43%$ 47.431 millions
Arcutis Biotherapeutics Inc 45.05%$ 45.052 millions
Zevra Therapeutics Inc 44.86%$ 44.864 millions
Xeris Biopharma Holdings Inc 44.16%$ 44.158 millions
Nephros Inc 43.60%$ 43.602 millions
Cardiff Oncology Inc 42.50%$ 42.500 millions
Neurocrine Biosciences Inc 41.24%$ 41.238 millions
Transmedics Group Inc 41.15%$ 41.149 millions
Uniqure N v 40.39%$ 40.394 millions
Harrow Inc 40.00%$ 40.001 millions
Mirum Pharmaceuticals Inc 39.63%$ 39.629 millions
Caredx Inc 39.29%$ 39.285 millions
Halozyme Therapeutics Inc 39.15%$ 39.154 millions
Eli Lilly And Company38.61%$ 38.613 millions
Sbc Medical Group Holdings Incorporated37.48%$ 37.478 millions
Myomo Inc 37.42%$ 37.416 millions
Editas Medicine Inc 37.41%$ 37.412 millions


About Zomedica Revenue Growth Rates (ZOMDF), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Zomedica Corp (CIK 1684144).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001104659-26-122658
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Zomedica Corp’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.